NEW YORK, NY / ACCESSWIRE / January 21, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
BRY Shareholders Click Here: https://www.zlk.com/pslra-1/berry-corporation-loss-submission-form?prid=12322&wire=1
NERV Shareholders Click Here: https://www.zlk.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?prid=12322&wire=1
PEN Shareholders Click Here: https://www.zlk.com/pslra-1/penumbra-inc-information-request-form?prid=12322&wire=1
* ADDITIONAL INFORMATION BELOW *
Berry Corporation (NASDAQ:BRY)
Lawsuit on behalf of investors who purchased: (a) Berry common stock pursuant and/or traceable to the Company's initial public offering conducted on or about July 26, 2018; or (b) Berry securities between July 26, 2018 and November 3, 2020, both dates inclusive
Lead Plaintiff Deadline: January 21, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/berry-corporation-loss-submission-form?prid=12322&wire=1
According to the filed complaint, (i) Berry had materially overstated its operational efficiency and stability; (ii) Berry's operational inefficiency and instability would foreseeably necessitate operational improvements that would disrupt the Company's productivity and increase costs; (iii) the foregoing would foreseeably negatively impact the Company's revenues; and (iv) as a result, the Offering Documents and the Company's public statements were materially false and/or misleading and failed to state information required to be stated therein.
Minerva Neurosciences, Inc. (NASDAQ:NERV)
NERV Lawsuit on behalf of: investors who purchased May 15, 2017 - November 30, 2020
Lead Plaintiff Deadline: February 8, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?prid=12322&wire=1
According to the filed complaint, during the class period, Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Penumbra, Inc. (NYSE:PEN)
PEN Lawsuit on behalf of: investors who purchased August 3, 2020 - December 15, 2020
Lead Plaintiff Deadline: March 16, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/penumbra-inc-information-request-form?prid=12322&wire=1
According to the filed complaint, during the class period, Penumbra, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; (2) that Penumbra did not adequately address the risk of the Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; (3) that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues; and (4) as a result, Penumbra's public statements as set forth above were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP